Business Segments Genscript Biotech Corporation

Stocks

1548

KYG3825B1059

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 09:08:14 16/06/2026 BST			5-day change	1st Jan Change
11.48 ^HKD	-2.71%		-4.97%	-7.57%

06-15	Genscript Associate Reports Promising Phase 1 Data for LB2501 in B-Cell Lymphoma	MT
06-03	Genscript Associate to Present Data for Lymphoma Drug at European Conference; Shares Surge 11%	MT

Sales 2025 by Business Segment

Sales 2025 by Geography

Historical Breakdown of Revenue by Business Segments

Gross Profit: Breakdown by Business Segment

Breakdown by Business Segment (USD)

Fiscal Period: December	2021	2022	2023	2024	2025
Life Sciences Tools and Services
Life-Science Services and Products	316M	361M	413M	455M	522M
Interest Expense	-	-	-3.27M	-	-
EBT	91.64M	42.81M	61.32M	81.82M	85.28M
Gross Profit	183M	198M	223M	235M	265M
Net Income	91.64M	42.81M	-	-	-
Biologics Development Services	81.35M	125M	109M	95.02M	389M
Interest Expense	-104K	-1.96M	-	-4.29M	-6.21M
Income Tax Expense	531K	2.06M	-	-	-
EBT	-148M	-7.71M	132M	-187M	134M
Gross Profit	25.59M	34.65M	23.97M	8.83M	258M
Net Income	-149M	-9.77M	-	-	-
Bio-Science Services and Products	-	-	-	-	-
Gross Profit	-	-	-	-	-
Preclinical Drug Development Services	-	-	-	-	-
Gross Profit	-	-	-	-	-
Life Sciences Research Catalog Products	-	-	-	-	-
Gross Profit	-	-	-	-	-
LifeScience Services and Products	-	-	-	-	-
Gross Profit	-	-	-	-	-
Operation Unit	9.59M	56.12M	53.15M	56.89M	66.06M
Interest Expense	-1.37M	-1.33M	-1.96M	-2.03M	-8.84M
Income Tax Expense	-	-6.84M	-	-	-
EBT	-51.4M	-25.88M	-25.53M	-64.68M	-683M
Gross Profit	5.23M	8.51M	8.57M	7.36M	9.23M
Net Income	-51.4M	-19.04M	-	-	-
Eliminations	-24.03M	-71.64M	-64.22M	-66.05M	-75.31M
Interest Expense	116K	842K	766K	747K	1.95M
EBT	-2.92M	1.2M	717K	-2.37M	868K
Gross Profit	-11.78M	-5.66M	-3.05M	-1.71M	-1.39M
Net Income	-2.92M	1.2M	-	-	-
Income Tax Expense	3.85M	-	-	-	-
Net Income	-3.85M	-	-	-	-
Biological Products
Industrial Synthetic Biology Products	38.57M	38.66M	43.05M	53.68M	57.95M
Interest Expense	-116K	-22K	-1.25M	-2.46M	-4.19M
Income Tax Expense	198K	446K	-	-	-
EBT	652K	3.62M	1.14M	985K	-7.87M
Gross Profit	11.32M	16.61M	16.55M	22.6M	22.95M
Net Income	454K	3.17M	-	-	-
Cell Therapy	89.79M	117M	285M	-	-
Interest Expense	-900K	-10.8M	-21.79M	-	-
Income Tax Expense	1K	625K	-	-	-
EBT	-386M	-446M	-520M	-	-
Gross Profit	89.79M	51.64M	141M	-	-
Net Income	-386M	-446M	-	-	-

Geographical Revenue Distribution History

Geographical breakdown of sales (USD)

Fiscal Period: December	2021	2022	2023	2024	2025
Mainland China	144M	167M	163M	177M	476M
Total Assets	362M	535M	552M	479M	494M
The United States of America	267M	332M	506M	265M	293M
Total Assets	191M	146M	247M	123M	127M
Europe	43.4M	53.28M	99.52M	80.93M	105M
Asia Pacific (Excluding Mainland China)	42.39M	59.01M	53.23M	53.08M	58.97M
Others	13.72M	14.56M	18.28M	18.5M	26.94M
Total Assets	21.52M	73.5M	149M	23.63M	26.58M
Asia Pacific (Excluding China and Japan)	-	-	-	-	-
Japan	-	-	-	-	-
China	-	-	-	-	-
Total Assets	-	-	-	-	-
North America	-	-	-	-	-